MedChunk
Medically reviewed

What Are DMARDs? Definition, Causes, and Treatment

Learn what DMARDs are, how disease-modifying antirheumatic drugs work, which inflammatory conditions they treat, common medication types, benefits, side effects, and monitoring requirements.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 16 min read

DMARDs (disease-modifying antirheumatic drugs) are prescription medicines that calm an overactive immune system, reduce inflammation, and slow the progression of certain autoimmune and inflammatory diseases. Unlike ordinary painkillers, they can help prevent long-term damage to joints and other tissues. They are commonly used to treat rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions.

What Does DMARD Stand For?

DMARD stands for disease-modifying antirheumatic drug. These medicines are designed to change the course of an inflammatory disease rather than simply relieve its symptoms.

The term has three important parts:

  • Disease-modifying: The medicine can slow disease progression and help prevent long-term tissue damage.
  • Antirheumatic: It is used to manage inflammatory conditions that affect joints and other body tissues.
  • Drug: It is a medication prescribed as part of a healthcare professional's treatment plan.

Many DMARDs work by reducing the activity of the immune system. This is important because certain autoimmune diseases develop when the immune system mistakenly attacks healthy tissues.

According to Cleveland Clinic, DMARDs can reduce inflammation, relieve pain, slow disease progression, and help protect bones and joints from damage.

Why Are DMARDs Prescribed? Conditions They Treat

DMARDs are prescribed for certain autoimmune and inflammatory diseases in which an overactive immune response contributes to ongoing inflammation or tissue damage. The particular medication depends on the condition being treated.

Some conditions managed with DMARDs include:

  • Rheumatoid arthritis: An autoimmune condition in which the immune system attacks the lining of the joints, causing inflammation and potentially permanent joint damage.
  • Psoriatic arthritis: An inflammatory condition associated with psoriasis that can affect joints, tendons, and other tissues.
  • Ankylosing spondylitis: An inflammatory condition that mainly affects the spine and joints between the spine and pelvis. Certain biologic DMARDs are used when appropriate.
  • Juvenile idiopathic arthritis: A group of inflammatory arthritis conditions that begin during childhood. Some children may require DMARD treatment.
  • Systemic lupus erythematosus: An autoimmune disease that can affect the joints, skin, kidneys, and other organs. Certain DMARDs help manage its inflammatory effects.
  • Other inflammatory conditions: Depending on the specific medicine, DMARDs may also be used for conditions such as inflammatory bowel disease, myositis, and certain forms of vasculitis.

Not every DMARD treats every condition. For example, conventional DMARDs such as methotrexate may be useful for peripheral joint inflammation, while biologic medicines may be selected for particular inflammatory pathways or disease patterns.

Healthdirect Australia explains that DMARDs are commonly used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile arthritis.

What Causes the Conditions That Require DMARDs?

DMARDs do not have a specific cause because they are medicines, not diseases. Instead, they are prescribed to manage conditions in which inflammation or abnormal immune activity contributes to tissue damage.

In autoimmune diseases, the immune system mistakenly identifies some healthy tissues as threats and attacks them. This can lead to persistent inflammation, pain, swelling, and damage to affected organs or joints.

For example, rheumatoid arthritis develops through an abnormal immune response that targets the joint lining. The exact cause is not fully understood, but several factors may contribute to its development.

  • Genetic factors: Certain inherited genetic variations may increase susceptibility to autoimmune diseases.
  • Immune system changes: Abnormal immune activity can contribute to inflammation and tissue injury.
  • Environmental exposures: Factors such as smoking may increase the risk of developing certain inflammatory conditions.
  • Hormonal influences: Hormonal changes may be associated with the development or activity of some autoimmune diseases.
  • Other biological factors: Infections and changes in the body's normal microbial environment have been investigated as possible contributors to some autoimmune conditions.

These factors do not establish why a particular person develops an autoimmune disease. The causes and contributing factors differ between conditions.

According to MedlinePlus, the exact cause of rheumatoid arthritis is unknown, although genetic, hormonal, and environmental factors may be associated with its development.

How Do DMARDs Work in the Body?

DMARDs work by changing parts of the immune response responsible for inflammation. Different medicines act on different immune cells, proteins, or chemical signals.

When the immune system remains overactive, inflammation can continue even when there is no infection or injury that needs to be fought. In inflammatory arthritis, this ongoing activity may gradually damage cartilage, bones, and surrounding tissues.

Depending on the medication, DMARDs may:

  • Reduce the activity of immune cells involved in inflammation.
  • Block specific proteins that send inflammatory signals.
  • Reduce the production or activity of substances involved in the inflammatory response.
  • Slow the progression of certain autoimmune diseases.
  • Help prevent or reduce long-term joint and tissue damage.

Not all DMARDs work in the same way. Some affect broader immune system activity, while others target particular immune pathways. This difference helps healthcare professionals select medicines based on the disease and an individual's treatment needs.

What Are the Main Types of DMARDs?

DMARDs are generally divided into three main groups: conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs. Each group acts on the immune system differently.

1. Conventional Synthetic DMARDs

Conventional synthetic DMARDs are chemically manufactured medicines that generally affect immune system activity more broadly. They are commonly used as initial disease-modifying treatments for several inflammatory conditions.

Examples include:

  • Methotrexate: One of the most commonly prescribed DMARDs for rheumatoid arthritis. It reduces immune activity and inflammation.
  • Hydroxychloroquine: Used in certain inflammatory and autoimmune conditions, including rheumatoid arthritis and lupus.
  • Sulfasalazine: Used for rheumatoid arthritis and some other inflammatory conditions.
  • Leflunomide: Helps control immune activity and is used to treat rheumatoid arthritis.
  • Azathioprine: An immunosuppressive medicine used for selected autoimmune and inflammatory conditions.

These medicines are generally taken by mouth, although methotrexate is also available as an injection. The exact administration schedule depends on the medication.

2. Biologic DMARDs

Biologic DMARDs are medicines made using living cells or biological processes. They target specific immune cells or proteins involved in inflammation.

Unlike conventional DMARDs, which often affect broader immune activity, biologic medicines are designed to act on particular parts of the immune system.

Examples include:

  • Adalimumab: A tumour necrosis factor (TNF) inhibitor that blocks a protein involved in inflammation.
  • Etanercept: A TNF inhibitor used for certain inflammatory arthritis conditions.
  • Infliximab: A biologic medicine that blocks TNF activity.
  • Abatacept: Reduces the activation of certain immune cells involved in inflammation.
  • Rituximab: Targets specific B cells that contribute to immune system activity.
  • Tocilizumab: Blocks interleukin-6 (IL-6), a protein involved in inflammation.

Biologic DMARDs are commonly given through injections under the skin or infusions into a vein. They may be considered when conventional treatments do not adequately control the disease or when a particular treatment approach is needed.

3. Targeted Synthetic DMARDs

Targeted synthetic DMARDs are chemically manufactured medicines that act on specific pathways involved in immune system activity. They are designed to block particular signals that contribute to inflammation.

One important group is Janus kinase (JAK) inhibitors. These medicines interfere with signalling pathways that help immune cells communicate.

Examples include:

  • Tofacitinib: A JAK inhibitor used for certain inflammatory conditions, including rheumatoid arthritis.
  • Baricitinib: A targeted medicine that blocks selected JAK enzymes.
  • Upadacitinib: A JAK inhibitor used for certain inflammatory and autoimmune conditions.

These medicines are generally taken as tablets. Their potential benefits and risks need to be considered carefully, particularly because some JAK inhibitors are associated with increased risks of serious infections, blood clots, and cardiovascular events in certain patients.

How Do Doctors Choose the Right DMARD?

There is no single DMARD that works best for everyone. A rheumatologist or another qualified specialist considers the underlying disease, its activity, previous treatments, and the person's overall health before selecting a medicine.

Important factors include:

  • Type of disease: Different inflammatory conditions respond to different medications.
  • Disease activity: The degree of inflammation and the risk of tissue damage influence treatment selection.
  • Previous treatment response: A different medicine may be needed if an earlier treatment was ineffective or poorly tolerated.
  • Other health conditions: Liver disease, kidney problems, infections, and cardiovascular conditions can affect medication choices.
  • Pregnancy plans: Some DMARDs are unsuitable during pregnancy or require treatment changes before conception.
  • Medication preferences: Tablets, self-injections, and hospital infusions have different practical requirements.

For rheumatoid arthritis, methotrexate is commonly used as an initial conventional DMARD when appropriate. Other medicines may be considered if it is unsuitable or does not provide sufficient disease control.

For more information about treatment selection, Mayo Clinic's rheumatoid arthritis treatment guidance describes conventional DMARDs, biologic agents, and targeted synthetic DMARDs as important treatment options.

What Does DMARD Treatment Involve?

DMARD treatment usually involves taking medication regularly, attending follow-up appointments, and having appropriate tests to check how well the treatment is working and whether it is causing side effects.

Starting Treatment

Before starting a DMARD, the healthcare professional reviews the medical history, current medications, and relevant health conditions. Depending on the medicine, initial assessments may include:

  • Complete blood count to check blood cell levels.
  • Liver function tests.
  • Kidney function tests.
  • Screening for infections such as tuberculosis or hepatitis when indicated.
  • Other assessments based on the specific medication and medical history.

How Long Do DMARDs Take to Work?

DMARDs generally do not provide immediate relief. Many take several weeks to begin working, and some may require a month or longer before their benefits become noticeable.

Conventional medicines such as methotrexate may take several weeks to produce meaningful improvement. Biologic medicines also generally require time before their full benefits can be assessed.

During this period, a healthcare professional may prescribe additional medicines, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or short-term corticosteroids, to help control symptoms while the DMARD begins working.

Monitoring During Treatment

Regular monitoring is an important part of DMARD treatment. Some medicines can affect blood cell counts, liver function, kidney function, or immune activity.

Depending on the prescribed medicine, monitoring may involve:

  • Periodic blood tests to check blood counts and organ function.
  • Assessments for infections or other medication-related complications.
  • Eye examinations for people taking hydroxychloroquine.
  • Screening for tuberculosis or hepatitis when appropriate.
  • Clinical assessments to measure disease activity and treatment response.

The frequency of these checks depends on the particular medicine, the person's health, and the stage of treatment.

What Are the Benefits of DMARDs?

The main benefit of DMARDs is their ability to control the underlying inflammatory disease process rather than only providing temporary symptom relief.

Potential benefits include:

  • Reduced inflammation: They can decrease inflammatory activity in affected joints and tissues.
  • Less joint damage: They can slow or prevent further damage caused by certain inflammatory diseases.
  • Improved physical function: Better disease control may make everyday activities easier.
  • Better symptom control: Reduced inflammation may help relieve joint pain, stiffness, and swelling.
  • Reduced disease activity: Some people achieve low disease activity or remission with appropriate treatment.

Remission means that disease activity has become very low or is no longer detectable using the measures applied by healthcare professionals. It does not necessarily mean that the underlying condition has been permanently cured.

What Are the Possible Side Effects of DMARDs?

DMARD side effects vary according to the medication, dose, and individual health factors. Some people experience few problems, while others may develop side effects that require additional monitoring or a change in treatment.

Common Side Effects

Possible side effects of certain DMARDs include:

  • Nausea or vomiting.
  • Diarrhoea or abdominal discomfort.
  • Headache.
  • Skin rash.
  • Hair loss.
  • Reduced appetite.
  • Fatigue.
  • Injection-site reactions.

For example, methotrexate may cause nausea, mouth ulcers, diarrhoea, and hair loss. Hydroxychloroquine can cause eye-related complications, while other medicines have different side-effect profiles.

Serious Risks to Be Aware Of

Some DMARDs can suppress immune system activity, increasing the risk of infections. Certain medicines may also affect blood cell counts or liver function.

Other important risks depend on the drug:

  • Serious infections: Some biologic and targeted medicines can increase the risk of infections, including tuberculosis reactivation in susceptible individuals.
  • Liver problems: Certain conventional DMARDs can affect liver function.
  • Blood abnormalities: Some medicines can reduce white blood cells, red blood cells, or platelets.
  • Eye complications: Long-term hydroxychloroquine treatment can rarely damage the retina.
  • Blood clots and cardiovascular events: Certain JAK inhibitors carry important warnings about these risks in particular patient populations.

Contact a healthcare professional promptly if you develop a fever, persistent cough, unusual weakness, or other possible signs of infection while taking a DMARD. Serious infections may not always produce typical symptoms when immune activity is suppressed.

DMARDs vs. NSAIDs: What Is the Difference?

DMARDs and NSAIDs are both used in the management of inflammatory arthritis, but they serve different purposes.

  • DMARDs: Change immune system activity and help slow the progression of inflammatory disease and prevent tissue damage.
  • NSAIDs: Reduce pain and inflammation but do not generally prevent the underlying disease from causing progressive joint damage.

For example, ibuprofen and naproxen are NSAIDs that may help reduce joint pain and swelling. Methotrexate is a DMARD that helps control the disease process itself.

Healthcare professionals may prescribe both types of medicines when appropriate because they have different roles in treatment.

Can DMARDs Be Taken Long Term?

Yes. Many people with chronic inflammatory diseases take DMARDs for extended periods to keep disease activity under control and reduce the risk of long-term damage.

Long-term treatment requires regular reviews to assess whether the medicine remains effective and safe. If the disease is well controlled for a sustained period, a specialist may consider gradually reducing the dose in selected circumstances.

However, stopping treatment without medical guidance can cause the disease to become active again. In some conditions, stopping all disease-modifying treatment may increase the risk of a flare or further tissue damage.

If a DMARD stops working or causes significant side effects, the healthcare professional may adjust the dose, change the medicine, or recommend a different treatment combination.

Important Precautions Before Taking DMARDs

Before starting treatment, discuss relevant health conditions, current medicines, and future pregnancy plans with the prescribing specialist.

Some precautions include:

  • Pregnancy and breastfeeding: Certain DMARDs can harm a developing baby or may not be suitable during breastfeeding. Methotrexate, for example, is not suitable during pregnancy.
  • Alcohol use: Alcohol may increase the risk of liver-related problems with certain medicines, particularly methotrexate. Ask about the appropriate restrictions for your prescription.
  • Vaccinations: Some live vaccines may be unsuitable during treatment. Vaccination plans should be reviewed before starting immune-suppressing medicines.
  • Other medications: Prescription drugs, over-the-counter medicines, and supplements may interact with DMARDs.
  • Infections: Tell your healthcare professional about current infections or a history of tuberculosis or hepatitis before starting treatment.

Follow the prescribed schedule carefully. Methotrexate used for inflammatory arthritis is generally taken once weekly, not daily. Taking it incorrectly can cause serious harm. If the schedule is unclear, confirm it with the prescribing clinician or pharmacist.

Never stop, restart, or change a DMARD dose on your own. If you develop a suspected infection or experience a concerning side effect, contact your healthcare team for instructions.

What Is the Long-Term Outlook With DMARD Treatment?

The long-term outlook depends on the underlying disease, how early treatment begins, the degree of inflammation, and how well the selected medicine works.

For many people with inflammatory arthritis, appropriate DMARD treatment can improve disease control, reduce symptoms, and lower the risk of permanent joint damage.

Some people achieve remission, while others continue to experience periods of increased disease activity despite treatment. A specialist may need to adjust the treatment plan over time to maintain the best possible control.

Early treatment, consistent medication use, regular monitoring, and timely communication about side effects all contribute to effective disease management.

Frequently Asked Questions

Common questions about DMARD medicines, their uses, benefits, and safety.

1. What is the most commonly prescribed DMARD?

Methotrexate is one of the most commonly prescribed conventional DMARDs, particularly for rheumatoid arthritis. Other options include hydroxychloroquine, sulfasalazine, and leflunomide. The appropriate medicine depends on the condition and individual health factors.

2. Are DMARDs the same as immunosuppressants?

Many DMARDs have immunosuppressive effects because they reduce or regulate immune system activity. However, DMARDs are a broader treatment category that includes medicines targeting specific inflammatory pathways as well as medicines that affect the immune system more generally.

3. How long does it take for DMARDs to work?

Many DMARDs take several weeks to begin providing noticeable benefits. Some conventional medicines may take a month or longer to work. The time required depends on the specific medication and the condition being treated.

4. Do DMARDs cure rheumatoid arthritis?

DMARDs do not cure rheumatoid arthritis, but they can control inflammation, slow disease progression, and help prevent joint damage. Some people achieve remission with treatment, although continued monitoring and medication may still be necessary.

5. Why are regular blood tests needed when taking DMARDs?

Some DMARDs can affect blood cell counts, liver function, or kidney function. Regular blood tests help healthcare professionals identify possible side effects early and determine whether treatment remains safe. The testing schedule depends on the medication being used.

Citations

  1. Cleveland Clinic – Disease-Modifying Antirheumatic Drugs (DMARDs)
  2. Healthdirect Australia – Disease-Modifying Antirheumatic Drugs for Arthritis
  3. Mayo Clinic – Rheumatoid Arthritis: Diagnosis and Treatment
  4. MedlinePlus – Rheumatoid Arthritis
Share this article